HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and...
solaci -
Learn More
Antiplatelet

WOEST 2 | Dual Versus Triple Antithrombotic Scheme in the Real World.

The WOEST study found a significant reduction in bleeding complications post PCI with oral anticoagulation indication (OAC)...
solaci -
Learn More
Antiplatelet

Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI

Coronary microvascular disfunction (CMD) is an important long-term prognosis predictor. CMD treatment can be an effective therapeutic...
solaci -
Learn More
Antithrombotic Anticoagulants

RESTORE | Using Rivaroxaban to Prevent Radial Artery Occlusion After an Intervention

Radial access has long demonstrated its benefit, but one of its most feared complications is radial artery...
solaci -
Learn More
Antiplatelet

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...
solaci -
Learn More
Antiplatelet

ACC 2022 | BENTRACIMAB

This study was presented in phase 2, in a healthy population between 50 and 80 years of...
solaci -
Learn More
Acute coronary syndromes

ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous...
solaci -
Learn More
Coronary Disease

ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite...
solaci -
Learn More